First online meeting of the International Advisory Board of WCRC for Personalized Medicine
On March 1, the International Advisory Board of the World-Class Research Centre for Personalized Medicine held its first meeting online.
The International Advisory Board was established to facilitate and comprehensively analyze the development of WCRC, assess the relevance of ongoing research and its compliance with the modern world trends. The Board includes 28 world leading experts in all areas of personalized medicine.
Director General of Almazov Centre, Academician of the RAS Evgeny Shlyakhto opened the meeting with a welcome speech and presented the mission, aims and history of WCRC and the Science national Project.
The second part of the meeting featured four presentations in each area of WCRC for Personalized Medicine:
- 1st area, Population genetics and polygenic non-communicable diseases — “Populational genetics and OMICs” by Nikita Artyomov, Head of Research Laboratory of Population Genetics.
2nd area, Unknown, rare and genetically determined diseases — “Rare, undiagnosed diseases. Genetic origin and new targets» by Anna Kostareva, Head of Research Laboratory of Molecular Transcriptomics and Gene Therapy.
3rd area, Oncology — “Personalized oncology” by Elena Ulrikh, head of Research Laboratory of Oncofertility and Onco-Gynecology.
4th area, Infectious diseases, microbial and antimicrobial therapy — “Infectious diseases and Personalized Medicine” by Alexander Suvorov, Head of Microbial Therapy Department.
The final keynote was the closing presentation by Prof. Alexandra Konradi, Deputy Director General for Research. She spoke about the prospects for international collaboration, functions and activities of the Board and presented a new Russian Journal for Personalized Medicine.
Following the presentation, the members engaged into a discussion, asked questions and shared their suggestions. In closing, the participants expressed the hope that the epidemiological situation would get better and the next meeting would be face to face.